Protective effect ofBifidobacterium infantisCGMCC313-2 on ovalbumin-induced airway asthma and β-lactoglobulin-induced intestinal food allergy mouse models

Abstract

AIMTo determine whether oral administration of Bifidobacterium infantis CGMCC313-2 (B. infantis CGMCC313-2) inhibits allergen-induced airway inflammation and food allergies in a mouse model.METHODSOvalbumin (OVA)-induced allergic asthma and β-lactoglobulin-induced food allergy mouse models were used in this study. Following oral administration of B. infantis CGMCC313-2 during or after allergen sensitization, histopathologic changes in the lung and intestine were evaluated by hematoxylin and eosin (HE) staining. In the allergic asthma mouse model, we evaluated the proportion of lung-infiltrating inflammatory cells. OVA-specific IgE and IgG1 levels in serum and cytokine levels in bronchoalveolar lavage fluid (BALF) were also assessed. In the food allergy mouse model, the levels of total IgE and cytokines in serum were measured.RESULTSOral administration of B. infantis CGMCC313-2 during or after allergen sensitization suppressed allergic inflammation in lung and intestinal tissues, while the proportion of infiltrating inflammatory cells was significantly decreased in the BALF of allergic asthma mice. Moreover, B. infantis CGMCC313-2 decreased the serum levels of total IgE in food allergy mice, and reductions in IgE and IgG1 were also observed in OVA-induced allergic asthma mice. The expression of interleukin-4 (IL-4) and IL-13 in both serum and BALF was suppressed following the administration of B. infantis CGMCC313-2, while an effect on serum IL-10 levels was not observed.CONCLUSIONB. infantis CGMCC313-2 inhibits the secretion of allergen-induced IgE, IL-4 and IL-13, and attenuates allergic inflammation.

Lactobacillus rhamnosus2016SWU.05.0601 regulates immune balance in ovalbumin‐sensitized mice by modulating expression of the immune‐related transcription factors and gut microbiota

“…51,52 Supplementation of Bifidobacterium improves balance in the intestinal microbiota, which benefits the prevention of allergic diseases, including airway inflammation, seasonal allergic rhinitis and intermittent asthma. [53][54][55] The results of the present study showed that the abundance of Bifidobacterium was increased after Lr-0601 treatment. Bifidobacterium also exhibited a significant correlation with immune balancerelated cytokine levels, which contributes to the reduction of IgE and attenuation of OVA-induced allergic responses.…”

New Perspectives in Food Allergy

“…Unlike allergen-specific immunotherapy, which requires the administration of the culprit food, new nonspecific therapeutic approaches targeting at the upstream events that regulate the function of both inducer and effector cells involved in FA, as well as at the IgE production, are independent of the allergen and aim to suppress the native and adaptive responses that drive the allergic reactions [2]. Personalized pharmacological and nutritional interventions [157], targeted therapies with biologics [158], including the monoclonal anti-IgE antibody omalizumab, dupilumab (anti-interleukin-4Ra), anti-IL-5 monoclonal antibodies (reslizumab and mepolizumab), and finally the reconstitution of a microbiome composition capable of inducing tolerance, for example, through Lactobacillus bifidus and Clostridium fragilis administration or through fecal transplantation [159][160][161], are innovative therapeutic tools that are becoming part of the modern FA treatment strategies.…”

Human Milk and Allergic Diseases: An Unsolved Puzzle

“…In addition, it was recently shown in a mouse study that the combination of B. infantis with HMO decreased GI inflammation and permeability [ 182 ]. Other mouse studies revealed that oral administration of Bifidobacteria is able to modulate inflammation associated with allergy [ 171 , 183 , 184 ]. However, the total HM oligosaccharide composition is likely to be very important and it should be realized that individual oligosaccharides in HM might have their own unique function on microbes, immune cells and epithelial cells.…”